ArticleTranslational cancer research2022
Downregulation of HNRNPM inhibits cell proliferation and migration of hepatocellular carcinoma through MAPK/AKT signaling pathway.
Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 10 citations in OpenAlex.
- circ_0004662 contributes to colorectal cancer progression by interacting with hnRNPM.International journal of oncology · 2025Article
- Disease prediction by network information gain on a single sample basis.Fundamental research · 2025Article
- Oncogenic LINC00698 suppresses apoptosis of melanoma stem cells to promote tumorigenesis via LINC00698-miR-3132-TCF7/hnRNPM axis.Cancer cell international · 2024Article
- hnRNPM protects against the dsRNA-mediated interferon response by repressing LINE-associated cryptic splicing.Molecular cell · 2024Article
- Knockdown of HNRNPM inhibits the progression of glioma through inducing ferroptosis.Cell cycle (Georgetown, Tex.) · 2023Article
- Therapeutic targeting of alternative splicing to inhibit hepatocellular carcinoma metastasis.Translational cancer research · 2022Article
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HNRNPM is reported to be involved in multiple malignancies, while the prognostic and biological role of HNRNPM in hepatocellular carcinoma remains still unknown. Methods: Public databases and tissue microarrays were employed to identify the expression pattern and prognostic value of HNRNPM in hepatocellular carcinoma. CCK8, cell migration assays and western blot were taken advantage of to discover the biological role of HNRNPM in hepatocellular carcinoma. Western blot and bioinformatics analysis were used to reveal the potential signaling pathways of HNRNPM in hepatocellular carcinoma. Results: High expression of HNRNPM was proved to be a poor independent prognostic factor for overall survival (OS) of hepatocellular carcinoma patients. Tissue microarrays and immunohistochemistry showed that HNRNPM protein level was upregulated in pancreatic cancer tissues compared with normal pancreas. Knockdown of HNRNPM suppressed significantly the capacities of proliferation and migration and alter epithelial mesenchymal transition of hepatocellular carcinoma cells. Downregulation of HNRNPM resulted in inhibition of the MAPK/AKT signaling pathway in hepatocellular carcinoma. Bioinformatics implied that HNRNPM might be a component of spliceosome to participate in hepatocellular carcinoma. Conclusions: This paper identified high expression of HNRNPM was a poor independent prognostic factor for OS of hepatocellular carcinoma and could participate in proliferation and migration through MAPK/AKT signaling pathways.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.